Skip to content
AnalystLens

BIOGEN INC. 8-K Report, Financial Results (Feb 13, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 13, 2024
Period End
February 13, 2024
Security
BIIB
In the record · 2016–202610-K1110-Q328-K112

BIIB filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 112 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Feb ’17Feb ’17
  2. Leadership change8-K · Sep ’20Sep ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Deal closed8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed February 13, 2024. Cited figures are marked; the original filing is the authoritative source.

Biogen reported fourth quarter and full year 2023 results on February 13, 2024.

Q4 2023 total revenue was $2.39 billiona, down 6% year over year (down 5% at constant currency), with GAAP diluted EPS of $1.71 and Non-GAAP diluted EPS of $2.95 (down 27%). The Non-GAAP EPS decline was driven in part by $0.35 per share of previously disclosed ADUHELM closeout costs. For full year 2023, revenue was $9.84 billion (down 3%), GAAP diluted EPS was $7.97, and Non-GAAP diluted EPS was $14.72 (down 17% from $17.67).

Multiple sclerosis product revenue fell 14% for the year, while rare disease (SPINRAZA, QALSODY, SKYCLARYS) grew 1% and biosimilars grew 3%. Full year 2023 GAAP results were also affected by the Reata acquisition, including about $393 millionb of post-acquisition equity compensation and $240 million of amortization and impairment of acquired intangibles. Management guided 2024 Non-GAAP diluted EPS to $15.00 to $16.00, implying roughly 5% growth at the midpoint.

Total revenue is expected to decline by a low- to mid-single-digit percentage, while core pharmaceutical revenue (product revenue plus Biogen's 50% share of LEQEMBI) is expected to be roughly flat, as MS erosion is offset by new launches. Contract manufacturing revenue is expected to fall significantly after batch commitments tied to the Hillerød sale were satisfied. Operating income is guided to grow at a low-double-digit percentage, supported by a better cost of sales ratio and the Fit for Growth program, which targets $1 billionc in gross and $800 million in net savings by 2025.

Balance sheet and cash flow were solid but leverage increased. Full year free cash flow was about $1.27 billiond, but Q4 free cash flow was negative (about -$53 million) because of a $393 million payment tied to Reata equity awards.

Cash and marketable securities were about $1.0 billion against roughly $6.9 billion of total debt, leaving net debt near $5.9 billion. No shares were repurchased in Q4, and about $2.1 billion remained under the existing buyback authorization.

02—Key points

Key Highlights

  1. Q4 2023 total revenue of $2.39B declined 6% YoY; full year revenue of $9.84B declined 3%, with MS product revenue down 14% for the year.
  2. Full year 2023 Non-GAAP diluted EPS was $14.72, down 17% from $17.67; GAAP diluted EPS was $7.97 versus $20.87 in 2022.
  3. 2024 guidance: Non-GAAP diluted EPS of $15.00 to $16.00 (about 5% growth at midpoint), with total revenue down low- to mid-single digits and core pharma revenue roughly flat.
  4. Operating income is guided to grow at a low-double-digit percentage in 2024, driven by improved cost of sales as a percentage of revenue and Fit for Growth savings of $800M net by 2025.
  5. Contract manufacturing revenue, which reached $899M in 2023 (including the Hillerød-related batches), is expected to be significantly lower in 2024.
  6. Net debt rose to about $5.9B at year-end 2023 after the Reata acquisition, and Q4 free cash flow was negative (about -$53M) due to a $393M Reata-related equity compensation payment.
  7. Early launch metrics: SKYCLARYS Q4 revenue of about $56M with ~1,000 patients on drug, ZURZUVAE Q4 revenue of about $2M, and LEQEMBI in-market revenue recorded by Eisai of about $7M in Q4.

03—Questions

Frequently Asked Questions

  1. Why did Non-GAAP EPS fall so sharply in 2023 and Q4?

    Non-GAAP EPS fell 17% for the full year and 27% in Q4 as revenue declined, MS product sales eroded (down 14% in 2023), and costs rose. Q4 was also hit by about $0.35 per share of ADUHELM closeout costs. Higher cost of sales as a percentage of revenue, driven by product mix and idle capacity charges, and the Reata-related R&D and SG&A costs also weighed on results.

  2. Is the 2024 guidance a return to growth?

    Partly. Management guides to about 5% Non-GAAP EPS growth at the midpoint and low-double-digit operating income growth, so profitability is expected to improve. However, total revenue is guided lower by a low- to mid-single-digit percentage, and core pharma revenue is expected to be only flat. Growth is therefore driven mainly by margin improvement and cost savings, not top-line expansion.

  3. What is driving the expected flat core pharma revenue in 2024?

    Continued declines in multiple sclerosis product revenue are expected to be offset by growth from newer launches, including SKYCLARYS, ZURZUVAE, and LEQEMBI (Biogen's 50% share). Lower contract manufacturing revenue after the Hillerød batch commitments were satisfied will weigh on total revenue, but it is excluded from core pharma revenue.

  4. How strong is Biogen's balance sheet and capital return posture after the Reata deal?

    Leverage increased, with net debt of about $5.9B against roughly $1.0B of cash and securities. Full year free cash flow of about $1.27B supports debt paydown; the company repaid about $350M of the $1B Reata term loan in 2023. No shares were repurchased in Q4 2023, though about $2.1B remains under the buyback authorization, so buybacks are likely to be constrained near term.

04—Continue

← View all 8-K filings